Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
API
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Almogran
2. Almotriptan
3. Axert
1. 181183-52-8
2. Almotriptan Maleate
3. Axert
4. Las 31416 D,l-malate Acid
5. Almotriptan (malate)
6. Almogran
7. Pnu-180638e
8. Almotriptan Malate [usan]
9. Almotriptan D,l-hydrogenmalate
10. Chebi:53781
11. Las-31416 D,l-malate Acid
12. Pjp312605e
13. 181183-52-8(almotriptan Malate)
14. Las-31416-d,l-malate-acid
15. N,n-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1h-indol-3-yl)ethan-1-amine 2-hydroxysuccinate
16. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate (1:1)
17. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedioate (1:1)
18. N,n-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1h-indol-3-yl]ethanamine;2-hydroxybutanedioic Acid
19. Pnu 180638e
20. Unii-pjp312605e
21. Sr-05000001986
22. Axert (tn)
23. Almotriptan Malate (usp)
24. 1-[[[2-(dimethyl-amino)ethyl]-1h-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate
25. Almotriptan Malate (axert)
26. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedionate (1:1)
27. Mls006010048
28. Schembl221131
29. Almotriptan Maleate [mi]
30. Chembl1200521
31. Dtxsid1044225
32. Almotriptan Malate [vandf]
33. Almotriptan Malate(pnu180638)
34. Hms3651a12
35. Hms3884p05
36. Almotriptan Malate [mart.]
37. Almotriptan Malate [usp-rs]
38. Almotriptan Malate [who-dd]
39. Bcp05632
40. Hy-b0383
41. Mfcd08067740
42. Pnu180638
43. S2096
44. (zznon-labelled)almotriptan-d6 Malate
45. Akos015950790
46. Bcp9000276
47. Ccg-269445
48. Pnu 180638
49. Almotriptan Malate [orange Book]
50. Almotriptan Malate [ep Monograph]
51. Almotriptan Malate [usp Monograph]
52. As-12142
53. Butanedioic Acid, Hydroxy-, Compd. With 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine (1:1)
54. Smr004701216
55. Ft-0661519
56. Sw219418-1
57. D02825
58. F14758
59. J-011571
60. Sr-05000001986-2
61. Q27124206
62. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate
63. 3-[2-(dimethylamino)ethyl]-5-(pyrrolidin-1-ylsulfonylmethyl )-1h-indole Malate
64. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine Hydroxybutanedioate
65. Butanedioic Acid, 2-hydroxy-, Compd. With N,n-dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-1h-indole-3-ethanamine (1:1)
Molecular Weight | 469.6 g/mol |
---|---|
Molecular Formula | C21H31N3O7S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 469.18827151 g/mol |
Monoisotopic Mass | 469.18827151 g/mol |
Topological Polar Surface Area | 160 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 612 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
2 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-03-09
Pay. Date : 2021-02-02
DMF Number : 25327
Submission : 2011-09-24
Status : Active
Type : II
Certificate Number : R0-CEP 2020-253 - Rev 00
Issue Date : 2022-01-25
Type : Chemical
Substance Number : 2970
Status : Valid
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm :
NDC Package Code : 14501-0073
Start Marketing Date : 2011-08-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26177
Submission : 2012-07-13
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-08
Pay. Date : 2012-11-06
DMF Number : 20424
Submission : 2007-03-22
Status : Active
Type : II
Date of Issue : 2022-06-22
Valid Till : 2025-07-28
Written Confirmation Number : WC-0117
Address of the Firm :
NDC Package Code : 65015-673
Start Marketing Date : 2015-01-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-31
Pay. Date : 2013-01-08
DMF Number : 18962
Submission : 2005-11-18
Status : Active
Type : II
Date of Issue : 2019-06-26
Valid Till : 2022-07-02
Written Confirmation Number : WC-0071
Address of the Firm :
NDC Package Code : 67835-5003
Start Marketing Date : 2008-02-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25225
Submission : 2011-08-16
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12475
Submission : 1997-04-17
Status : Inactive
Type : II
Date of Issue : 2019-08-13
Valid Till : 2021-08-12
Written Confirmation Number : WC117Amendment
Address of the Firm :
NDC Package Code : 65015-673
Start Marketing Date : 2015-01-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Almotriptan Malate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Almotriptan Malate, including repackagers and relabelers. The FDA regulates Almotriptan Malate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Almotriptan Malate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Almotriptan Malate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Almotriptan Malate supplier is an individual or a company that provides Almotriptan Malate active pharmaceutical ingredient (API) or Almotriptan Malate finished formulations upon request. The Almotriptan Malate suppliers may include Almotriptan Malate API manufacturers, exporters, distributors and traders.
click here to find a list of Almotriptan Malate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Almotriptan Malate DMF (Drug Master File) is a document detailing the whole manufacturing process of Almotriptan Malate active pharmaceutical ingredient (API) in detail. Different forms of Almotriptan Malate DMFs exist exist since differing nations have different regulations, such as Almotriptan Malate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Almotriptan Malate DMF submitted to regulatory agencies in the US is known as a USDMF. Almotriptan Malate USDMF includes data on Almotriptan Malate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Almotriptan Malate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Almotriptan Malate suppliers with USDMF on PharmaCompass.
A Almotriptan Malate CEP of the European Pharmacopoeia monograph is often referred to as a Almotriptan Malate Certificate of Suitability (COS). The purpose of a Almotriptan Malate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Almotriptan Malate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Almotriptan Malate to their clients by showing that a Almotriptan Malate CEP has been issued for it. The manufacturer submits a Almotriptan Malate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Almotriptan Malate CEP holder for the record. Additionally, the data presented in the Almotriptan Malate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Almotriptan Malate DMF.
A Almotriptan Malate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Almotriptan Malate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Almotriptan Malate suppliers with CEP (COS) on PharmaCompass.
A Almotriptan Malate written confirmation (Almotriptan Malate WC) is an official document issued by a regulatory agency to a Almotriptan Malate manufacturer, verifying that the manufacturing facility of a Almotriptan Malate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Almotriptan Malate APIs or Almotriptan Malate finished pharmaceutical products to another nation, regulatory agencies frequently require a Almotriptan Malate WC (written confirmation) as part of the regulatory process.
click here to find a list of Almotriptan Malate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Almotriptan Malate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Almotriptan Malate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Almotriptan Malate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Almotriptan Malate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Almotriptan Malate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Almotriptan Malate suppliers with NDC on PharmaCompass.
Almotriptan Malate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Almotriptan Malate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Almotriptan Malate GMP manufacturer or Almotriptan Malate GMP API supplier for your needs.
A Almotriptan Malate CoA (Certificate of Analysis) is a formal document that attests to Almotriptan Malate's compliance with Almotriptan Malate specifications and serves as a tool for batch-level quality control.
Almotriptan Malate CoA mostly includes findings from lab analyses of a specific batch. For each Almotriptan Malate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Almotriptan Malate may be tested according to a variety of international standards, such as European Pharmacopoeia (Almotriptan Malate EP), Almotriptan Malate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Almotriptan Malate USP).
LOOKING FOR A SUPPLIER?